Cara Therapeutics (CARA) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CARA Hot Sheet
Join SI Premium – FREE
Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.19), $0.08 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.77 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Sprout Social (SPT) Tops Q3 EPS by 16c; Offers Guidance
- Everus Construction Group, Inc. (ECG) Tops Q3 EPS by 101c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
